TScan Therapeutics, Inc. (TCRX) Discusses Strategic Refocus on In Vivo Cell Therapy for Solid Tumors and Pausing of Phase III Heme Study Transcript
Crude Oil Moves Higher; US Factory Orders Rise In July - Credo Technology Group (NASDAQ:CRDO), Purple Bio
TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction - TScan Therapeutics (NASDAQ:TCRX)
Dow Surges Over 200 Points; Ollie's Bargain Outlet Shares Gain After Q2 Earnings - Ollie's Bargain Outlet